Sandu Pharmaceuticals appoints Dave & Dave as statutory auditors for five years

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Sandu Pharmaceuticals appointed M/s Dave & Dave as statutory auditors for FY27 to FY31
  • Outgoing auditors M/s Dileep and Prithvi completed two five-year terms
  • Shareholders approved the move at the AGM held on September 11, 2026
  • New firm holds valid peer review certificate until March 31, 2028
powered bylight_fuzz_icon
50755534

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals appointed M/s Dave & Dave as its statutory auditors for a five-year term covering financial years 2026-27 to 2030-31. The company’s shareholders approved the appointment at their annual general meeting held on September 11, 2026.

The new audit firm will hold office from the conclusion of the 41st AGM until the conclusion of the 46th AGM in 2031. This appointment follows the mandatory rotation of auditors under Section 139(2) of the Companies Act, 2013.

Auditor Transition Details

The tenure of the outgoing statutory auditors, M/s Dileep and Prithvi, expired with the conclusion of the 41st AGM. The firm had completed two consecutive five-year terms as the company’s statutory auditor. Consequently, they were ineligible for reappointment.

Particulars Details
Outgoing Auditors M/s Dileep and Prithvi (Firm Reg No. 122290W)
Incoming Auditors M/s Dave & Dave (Firm Reg No. 102163W)
Term Duration Five years (FY27 to FY31)
Reason for Change Completion of tenure

New Auditor Profile

M/s Dave & Dave is a Mumbai-based partnership firm established in 1989. The firm holds Peer Review Certificate No. 020259, valid from March 25, 2025, to March 31, 2028. It comprises two partners, two associates, and ten other staff members.

The firm provides statutory, internal, management, stock, and tax audits. Its partners possess professional experience ranging from 25 to 35 years in taxation, audit, project finance, and GST audit. The firm has served various listed companies, private entities, public sector undertakings, and banking institutions.

Regulatory Compliance

The company disclosed that M/s Dave & Dave is not related to any directors, key managerial personnel, or promoters of Sandu Pharmaceuticals. The change in auditors was made in accordance with the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and the Companies Act, 2013. No concerns or issues were raised by the outgoing auditors regarding their tenure.

Historical Stock Returns for Sandu Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-2.25%-5.39%-7.01%+5.74%-22.30%0.0%

How might the transition from M/s Dileep and Prithvi to M/s Dave & Dave impact Sandu Pharmaceuticals' internal control frameworks and audit methodologies?

Given M/s Dave & Dave's extensive experience in banking and project finance, will this influence Sandu Pharmaceuticals' approach to capital structure or debt financing strategies?

Are there any anticipated changes in audit fees or service scope under the new five-year term compared to the previous auditor's tenure?

like18
dislike

Sandu Pharmaceuticals schedules 41st AGM for September 11, 2026

scanx
Reviewed by
Ashish TScanX News Team
Key Highlights

Sandu Pharmaceuticals Limited will hold its 41st AGM on September 11, 2026, via video conference. Remote e-voting opens on September 8 and closes on September 10. The record date for dividend eligibility is September 4, 2026.

powered bylight_fuzz_icon
48752833

*this image is generated using AI for illustrative purposes only.

Sandu Pharmaceuticals has scheduled its 41st Annual General Meeting (AGM) for Friday, September 11, 2026. The meeting will be conducted via Video Conference or Other Audio-Visual Means in compliance with SEBI regulations and the Companies Act, 2013.

Meeting Details

The AGM is set to begin at 4:30 pm IST. Shareholders can access the Notice of AGM, explanatory statements, and the Annual Report for FY26 from the company’s website and the BSE Limited portal. The notice was published in Navhind Times and Navprabha on August 20, 2026.

E-Voting Process

Members holding shares as of the cut-off date of Friday, September 4, 2026, are eligible to vote. The company has enabled remote e-voting through National Securities Depository Limited (NSDL).

  • Remote E-Voting Window: Commences at 10:00 am IST on Tuesday, September 8, 2026, and ends at 5:00 pm IST on Thursday, September 10, 2026.
  • Voting During AGM: Members present via VC/OAVM who have not voted remotely may cast their votes during the meeting.
  • Scrutinizer: Swapnil Dixit, ACS, of M/s. Swapnil J Dixit & Associates, has been appointed to scrutinize the voting process.

Record Date and Dividend

The Register of Members and Share Transfer Books will remain closed from September 4, 2026, to September 11, 2026, inclusive. Any dividend declared for FY26 will be paid to members recorded on the register as of the cut-off date.

Historical Stock Returns for Sandu Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
-2.25%-5.39%-7.01%+5.74%-22.30%0.0%

What specific strategic initiatives or capital allocation plans is Sandu Pharmaceuticals expected to propose for approval at the upcoming AGM?

How might the dividend payout ratio for FY26 compare to previous years, and what does this signal about the company's cash flow health and growth priorities?

Are there any anticipated changes to the board of directors or executive compensation structures that shareholders should be aware of before voting?

like17
dislike

More News on Sandu Pharmaceuticals

1 Year Returns:-22.30%